Eli Lilly has been on an absolute tear lately, rallying about 28% from its lows on March 7 to new all-time highs above $400 per share...
Juanmonino | E+ | Getty Images Seniors with early Alzheimer’s disease will face major hurdles to get treated even if promising new drugs roll out more...
Chiquita Brooks-LaSure testifies before the Senate Finance Committee during her nomination hearing to be administrator of the Centers for Medicare & Medicaid Services in Washington on...
A person skateboards past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Adam Glanzman | Bloomberg | Getty Images Biogen isn’t worried about...
Research at Biogen Source: Biogen Alzheimer’s patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai shows. The Japanese drugmaker...
Medical bottles and syringe are seen with Eli Lilly and Company logo displayed on a screen in the background in this illustration photo taken in Krakow,...
A pedestrian walks past Biogen Inc. headquarters in Cambridge, Massachusetts, U.S., on Monday, June 7, 2021. Adam Glanzman | Bloomberg | Getty Images The Food and...
The Veterans’ Health Administration will cover Eisai and Biogen‘s Alzheimer’s treatment Leqembi for some patients, the companies announced on Monday. In a statement, Eisai said veterans...
Andrew Brookes | Image Source | Getty Images The Food and Drug Administration will make a decision on whether to fully approve Eisai‘s and Biogen‘s Alzheimer’s...
Medicare will not provide broader coverage of the Alzheimer’s drug Leqembi until it receives more evidence that the treatment is reasonable and necessary, according to the...
